젠큐릭스

229000KOSDAQ의료용품 및 기타 의약 관련제품 제조업

53.3 / 100

Reference Date: 2026-06-10

Financial Score20.0 / 40

News Sentiment21.3 / 25

Momentum2.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Plunged 42.2% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Genex develops molecular diagnostic products and services based on liquid biopsy technology, focusing on cancer prognosis and companion diagnostics. Its key products include the breast cancer prognosis test 'GenesWell BCT' and the lung cancer companion diagnostic test 'GenesWell ddEGFR Mutation Test'. The company is also advancing early cancer detection through liquid biopsy products and CTC technology research.

Number of Employees

75people

Average Salary

57.9M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 19.194.0Point

PBR

3.17Industry Average 1.300.0Point

2.4x industry avg (risky)

ROE

-47.25Industry Average -4.893.5Point

9.7x industry avg (excellent)

Debt Ratio

2.55Industry Average 6.866.5Point

Half of industry avg (excellent)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲72.2% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲23.3% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -102.0% (improving, 3yr)

Detailed News Sentiment

2 totalPositive 2Neutral 0Negative 0Average Sentiment Score 85

Positive
젠큐릭스, 중국 궈런과 유방암 진단검사 공급 계약…中시장 진출
젠큐릭스의 유방암 예후진단 검사 서비스가 중국 궈런 인터내셔널 메디컬 그룹과의 계약으로 중국 시장 진출이 확정되어 긍정적인 시장 반응을 기대할 수 있다.
Positive
젠큐릭스 Droplex POLE 연구, 국제학술지 게재
젠큐릭스의 드롭플렉스 POLE 뮤테이션 테스트가 국제 학술지 게재를 통해 진단 정확도와 임상적 가치를 입증하며 긍정적인 평가를 받았다.

Detailed Momentum

52-week position1.0Point

Near 52w low (17%, downtrend)

Current 2,215Won52-week high 5,87052-week low 1,428

1-month return0.0Point

1m -42.24% (strong drop)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-05